DISEASE INDICATIONS: Myelofibrosis

MANUFACTURER: Impact Biomedicines, Inc.

USAGE: Oral

MEDICINE APPROVED BY:

European Medical Agency (EMA)

Food and Drug Administration (FDA)

Inrebic (fedratinib) is an oral medication used to treat myelofibrosis by inhibiting the activity of the JAK2 protein. The medication helps to reduce the production of abnormal cells in the bone marrow and improve symptoms such as fatigue and enlarged spleen.